SuperworthMetaVia MTVA
- Market cap
- $9.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
MetaVia's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $2.3M+301% | $3.9M+1167% | $4.9M+670% | $8.1M+242% | $4.5M+97% | $4.1M+5% | $2.3M−53% | $2.3M−71% | $1.9M−58% | $241K−94% | $2.1M−10% | $3.5M+50% |
| SG&A | $1.6M−37% | $1.8M−6% | $2M+5% | $2M+39% | $1.7M+9% | $1.5M−15% | $1.6M−21% | $2M−1% | $1.6M−10% | $1.8M+18% | $1.9M+23% | $1.9M−4% |
| −$3.9M+25% | −$5.7M−46% | −$6.9M+173% | −$10.1M+165% | −$6.3M+61% | −$5.6M−1% | −$3.9M−44% | −$4.3M−57% | −$3.5M−45% | −$2M−63% | −$4M+4% | −$5.4M+25% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$3.8M+23% | −$5.3M+14% | −$6.7M+158% | −$10.1M+1270% | −$5.7M+48% | −$5.2M−3% | −$3.7M−45% | −$4M−60% | −$3.4M−40% | −$1.9M−63% | −$3.8M+4% | −$5.3M+33% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | −$3.8M+23% | −$5.3M+14% | −$6.7M+158% | −$10.1M+1270% | −$5.7M+48% | −$5.2M−3% | −$3.7M−45% | −$4M−60% | −$3.4M−40% | −$1.9M−63% | −$3.8M+4% | −$5.3M+33% |
| −$8.25−97% | −$11.44−79% | −$14.52+159% | −$20.35+1133% | −$6.05−27% | −$5.61−51% | −$3.93−73% | −$2.87−86% | −$1.54−75% | −$0.85−85% | −$0.79−80% | −$0.90−69% | |
| 461.4K+4469% | 462.7K+438% | 462.7K+1% | 493.5K+7% | 928.6K+101% | 931.2K+101% | 933.1K+102% | 1.4M+182% | 2.2M+139% | 2.3M+145% | 4.9M+421% | 5.9M+327% |
R&D: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
SG&A: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Operating income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Net income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
EPS, diluted: 9 periods, Q1 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY15: share-days: the 6-month average less the second quarter's. Q3 FY15: a loss quarter: its basic count, share-days: the 9-month average less the 6-month, weighted by days. 10 periods, Q4 FY15 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x11).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest MetaVia's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MTVAMetaVia | $9.1M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on MetaVia
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .